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ABSTRACT: The reaction of a readily obtained chiral branched homoprenylamonium 
salt with a range of aldehydes, including aliphatic substrates, affords the corresponding 
linear isomers in good yields and enantioselectivities. 
 
Introduction 
Allylation of imines is one of the most valuable tools to build enantioenriched 
homoallylic amines, using either catalytic1 or non-catalytic2 methods. In addition to the 
challenge posed by the stereoselection, regioselectivity is a very important issue in 
allylation reactions. Generally, -substituted allylic reagents furnish the corresponding 
branched products (-adducts) with high selectivity. In particular, very few examples of 
α-regioselective prenylation of imines have been reported. The first useful protocol was 
reported by H. Yamamoto in 1996 and consists in the addition of in-situ generated 
prenyl barium reagent to imines at 0 ºC.3 Although this elegant procedure showed 
excellent levels of regioselectivity in the examples examined, it has some practical 
limitations related to the formation and manipulation of activated (Rieke) barium under 
anhydrous conditions. In the past two decades very little progress has been made in this 
area. Recently it was reported that prenylhafnium reagent, formed from 
prenylSnBu3/HfCl4, adds to imines in propionitrile with excellent α-selectivity.4 More 
recently, it was found that prenyl zinc reagent in combination with 1,3-dimethyl-2-
imidazolidinone at 120 ºC can also be used for the α-addition to imines.5 Furthermore, 
the cross-coupling of imines with 2-methyl-3-buten-2-ol, mediated by an in-situ formed 
low-valent titanium reagent, has also been successfully used.6 Very recently, the linear 
prenylation of imines has also been accomplished under transfer hydrogenation 
conditions.7 Surprisingly, to our best knowledge, only one example of α-prenylation of 
imines with moderate enantioselectivity (80:20 er) has been reported to date.3 
Enantioenriched homoprenyl amines have been recently prepared by α-deprotonation of 
amines with n-BuLi/(−)-sparteine, to give a chiral organolithium that was quenched 
with prenyl bromide. This method has been successfully applied to N-Boc pyrrolidine 
and benzylamines.8  
Homoprenylsulfonamides have been extensively used for the synthesis of pyrrolidines 
through 5-endo-trig cyclizations promoted by triflic acid9 or iodine.10 Furthermore, the 
utility of homoprenyl amine derivatives as building blocks of bioactive natural 
compounds has also been illustrated under cationic11 or radical12 conditions. Given that 
the protocols available for α-regioselective prenylation of imines remain scarce, the 
synthetic applications of the corresponding linear amines are still underexploited. In this 
context we decided to develop an alternative method that allows access to a variety of 
enantioenriched linear homoprenylamines from an easily available chiral substrate. 
Our approach is based on the precedented 2-azonia-Cope rearrangement of chiral 
iminiums derived from branched homoallylic primary amines. This strategy was first 
employed by using a derivative of (1R)-camphorquinone as a chiral template13 and more 
recently in catalytic methods that use chiral Brønsted acids as ligands for the 
asymmetric induction via a chiral ion-pair.14 To our surprise, this approach has never 
been used as a general method to generate homoprenylic amines.15 We reasoned that 
chiral -adducts, easily available from the addition of prenyl organometallic reagents to 
imine derivatives, could act as convenient aminoprenyl donors to other aldehydes. In 
our approach, the geminal methyl groups are expected to sterically promote the 
rearrangement to an iminium ion with an internal more stable double bond (Scheme 1). 
In this model it is assumed that the (E)-iminium intermediate rearranges through a 
closed chair-like transition state in which the bulkier substituent (R1) is placed in 
equatorial position. The fact that this favored transition state involves two gauche 
interactions of the R1 group with the geminal methyl groups anticipated a more 
challenger enantioselection than in other related transfer aminoallylations. 
 
Scheme 1. Working model for enantioselective transfer aminoprenylation of aldehydes. 
 
Results and discussion 
To prepare the chiral donors we used the indium mediated one-pot protocol recently 
developed in our research group for the diastereoselective aminoallylation of 
aldehydes.16 The corresponding branched homoprenylic sulfinamines were obtained 
with high γ-regio and stereoselectivity. After conventional acidic deprotection, the 
corresponding enantioenriched17 amine hydrochlorides 3a and 3b were obtained in 
quantitative yield. (Scheme 2). 
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Scheme 2. Enantioenriched homoprenyl amine donors. 
 
Initially, we screened both aminoprenyl chiral donors using 3-phenylpropanal as 
acceptor. The conditions chosen were very simple. The corresponding -adduct 2 was 
in-situ deprotected and after removal of all volatile compounds under vacuum, a 
solution of 3-phenylpropanal (1.2 equiv) in the appropriate solvent was added to the 
chiral donor 3 and submitted to the reaction conditions indicated in Table 1. While the 
best yield in the sigmatropic rearrangement at 25 ºC was obtained in CH2Cl2 with the 
donor 3a (entry 1), the best enantioselectivity was obtained using the donor derived 
from cinnamaldehyde (3b, entry 2). In the latter case, it was necessary to quench the 
reaction mixture with HONH2·AcOH in MeOH,13 probably due to the better stability of 
the conjugate iminium formed after the rearrangement. We were encouraged by the 
result obtained with 3b because this donor was obtained enantiomerically pure in 
excellent yield, and the absolute configuration of its enantiomer (ent-2b) was 
ascertained by X-ray crystal diffraction analysis (see ESI). More importantly, this result 
proved that compound 3b could act as chiral aminoprenyl transfer agent to different 
aldehydes. In order to avoid the quenching with HONH2·AcOH, it was examined the 
addition of 5 equivalents of H2O to the reaction mixture but only starting 3b was 
recovered (entry 3).The reaction was found to proceed with similar enantioselectivity in 
toluene but in lower yield (entry 4). When the reaction was run at 40 ºC, the same 
enantioselectivity was obtained for 4a but in a shorter reaction time (12 h, entry 5). We 
examined the addition of different molecular sieves to the reaction mixture (entries 6-8), 
however we observed slightly lower yields and enantioselectivities in all cases. More 
importantly, we also demonstrate that the reaction proceed in good yield in the presence 
of substoichiometric amounts of camphorsulfonic acid (entries 9, 10). Unfortunately, 
the enantioselectivities obtained with both enantiomeric chiral Brønsted acids were 
lower than with the hydrochloride 3b. 
Table 1. Screening of different reaction conditions. 
 
Entry 3 Conditionsa t (h) Yieldb erc 
1 3a CH2Cl2, 25 ºC 24 80%d 83:17 
2 3b CH2Cl2, 25 ºC 24 65% 88:12 
3 3b CH2Cl2,d 25 ºC 24 0 - 
4 3b Toluene, 25 ºC 24 50% 88:12 
5 3b CH2Cl2, 40 ºC 12 78% 88:12 
6 3b CH2Cl2, 40 ºC, 3Ǻ MS 12 70% 82:18 
7 3b CH2Cl2, 40 ºC, 4Ǻ MS 12 74% 82:18 
8 3b CH2Cl2, 40 ºC, 5Ǻ MS 12 71% 86:14 
9 3be CH2Cl2, 40 ºC, (+)-CSA 12 70% 82:18 
10 3be CH2Cl2, 40 ºC, (−)-CSA 12 74% 82:18 a Unless otherwise specified, all reactions were run in dry solvents 
and quenched with HONH2·HCl in MeOH at 40 ºC. b Isolated yield. c Determined by HPLC analysis of benzoyl derivative. d 5 equiv of 
H2O were added. e Free amine of 3b and 10 mol% of CSA was used. 
 
 
Having found a simple and reliable set of conditions for the enantioselective 
aminoprenylation of aldehydes we set about determining the scope and limitations. A 
range of aldehydes was examined, affording the results shown in Table 2. Given that 
enolizable aliphatic aldehydes would furnish iminium ions which are in equilibrium 
with their enamines, these substrates are more challengers. We were pleased to find that 
this subclass of aldehydes (Table 2, entries 1-5) were suitable substrates for this 
protocol, affording the corresponding linear homoprenylic amines in good yields and 
moderate to good enantioselectivities. Interestingly the use of the chiral (S)-citronellal 
resulted in a match (entry 5) and mismatched (entry 4) combination with the chiral 
donor (ent-3b or 3b, respectively) that impacted both, the isolated yield and the 
enantioselectivity. A limitation to this protocol was encountered with benzaldehyde, 
which gave very little conversion to isolate a pure product. However, cinnamaldehyde 
(entry 6) and aromatic aldehydes with diverse electron-withdrawing substituents (entries 
7-12) furnished the corresponding enantioenriched products (≥ 89:11 er) in decent 
yields. Importantly, our protocol tolerates various functional groups -including nitro, 
halogens, alkenes and alkoxycarbonyl groups- in the reactive aldehyde. We thus 
decided to take advantage of this chemoselectivity. When 3-methoxycarbonyl-propanal 
was used in our standard protocol, the corresponding -lactam was directly obtained 
(entry 13). However, the use of 5-ethoxycarbonyl pentanal lead to the formation of the 
corresponding acyclic aminoprenyl derivative in excellent yield (entry 14). More 
interestingly, when 6-oxoheptanal was used, the aminoprenylation was followed by 
intramolecular iminium formation. Upon reduction with NaCNBH3, the corresponding 
cis-2,7-azepane derivative 4o was obtained in reasonable overall yield and good 
enantioselectivity (entry 15). 
Table 2. Substrate scope. 
 
Entry Product 4 Yielda erb/dr 
1c 
 
4a 78 % 88:12 er 
2 
 
4b 70 % 89:11 er 
3 
 
4c 65 % 82:18 er 
4d 
 
4d 63 % 81:19 dre 
5d,f 
 
4e 75 % 93:7 dre 
6 
 
4f 80 % 89:11 er 
7 
 
4g 52 % 92:8 er 
8 
 
4h 45 % 89:11 er 
9c 
 
4i 30% 89:11 er 
10 
 
4j 50 % 89:11 er 
11 
 
4k 83 % 90:10 er 
12 
NH2
Me
Me
F
NO2  
4l 60 % 94:6 er 
13c 
 
4m 75 % 88:12 er 
14c 
 
4n 87 % 85:15 er 
15c,g 
 
4o 37 % 86:14 er 
[a] Isolated yields after column chromatography. [b] Determined by 
HPLC analysis (CHIRALCEL OD-H). [c] The enantiomer was also 
obtained from ent-3b with the same selectivity. [d] (S)-citronellal with 
98:2 er was used. [e] Determined by 13C-NMR analysis. [f] ent-3b was 
used as chiral donor. [g] NaCNBH3 was used to quench the reaction. 
 
The assignment of the absolute configuration of the major enantiomer of amine 4a 
was performed by 1H-NMR analysis of its (R)-MPA amide, with and without 
Ba(ClO4)2. As described by the group of Riguera, the addition of Ba2+ to the NMR 
sample of 4a should facilitate the formation of a chelate.18 This equilibrium shift from 
an antiperiplanar to a synperiplanar conformation  leads to an increase shielding of the 
vinylic and methyl signals by the phenyl group of the MPA auxiliary (Figure 1). The 
same analysis was performed to revealed the absolute configuration of the major 
enantiomers of 4b and 4k (see ESI for details). Importantly, the inversion of the 
configuration at the stereogenic center from donor (S)-3b to the major enantiomer of 4 
is predicted by our working model (Scheme 1).  
 
 
Figure 1 Absolute configuration of 4a by 1H-NMR analysis of its (R)-MPA amide. 
 
It is worth noting that although this protocol requires the use of stoichiometric 
amounts of chiral tert-butyl sulfinamide, some practical procedures have been described 
for recycling this auxiliary upon removal.19 Moreover, the ready availability of both 
antipodes of tert-butyl sulfinamide allows access to both enantiomeric forms of the 
corresponding linear homoprenylamine.20 
The potential of the enantioenriched homoprenylamines as building blocks of 
pyrrolidines was illustrated by preparing the p-nosylate of 4a and 4n, which upon 
treatment with substoichiometric amounts of triflic acid at 0 ºC underwent very smooth 
and efficient intramolecular hydroamination (Scheme 3).9a, 9b 
 
 
Scheme 3. Pyrrolidine synthesis from compounds 4a and 4n. 
 
Conclusions 
A general protocol to enantioenriched linear homoprenylic amines has been 
developed. The procedure is based in the transfer aminoprenylation of aldehydes from a 
unique chiral branched donor through a 2-azonia-Cope rearrangement. Importantly, 
both enantiomeric forms of the chiral donor are obtained from commercially available 
starting materials after only two synthetic operations. To the best of our knowledge, this 
represents the most general and easy to reproduce protocol that gives access to these 
highly versatile building blocks. Therefore, we hope that this methodology may find 
wide applications in synthetic organic chemistry. 
 
Experimental 
General Remarks:  
(Rs)-N-tert-Butylsulfinyl amine and its enantiomer were a gift of Medalchemy (> 99% 
ee by chiral HPLC on a Chiracel AS column, n-Hexane/i-PrOH 90:10, 1 mL/min, 
=222 nm). TLCs were performed on silica gel 60 F254, using aluminum plates and 
visualized with phosphomolybdic acid (PMA) or ninhydrine stain. Flash 
chromatographies were carried out on handpacked columns of silica gel 60 (230- 400 
mesh). Melting points are uncorrected. Optical rotations were measured using a 
polarimeter with a thermally jacketted 5 cm cell at approximately 20 ºC and 
concentrations (c) are given in g/100 mL. Infrared analyses were performed with a 
spectrophotometer equipped with an ATR component; wavenumbers are given in cm-1. 
GC analyses were obtained with an HP-5 column (30 m × 0.25 mm, i.d. × 0.25 µm) and 
an EI (70 EV) detector; the temperature program was as follows: hold at 60 °C for 3 
min, ramp from 60 to 270 °C at 15 °C/min, hold at 270 °C for 10 min. Mass spectra (EI) 
were obtained at 70 eV; and fragment ions in m/z with relative intensities (%) in 
parentheses. HRMS analyses were also carried out in the electron impact mode (EI) at 
70 eV using a quadrupole mass analyzer or in the electrospray ionization mode (ES+) 
using a TOF analyzer. 1H NMR spectra were recorded at 300 or 400 MHz, using CDCl3 
or CD3CN as the solvent and TMS as internal Standard (0.00 ppm); the data is being 
reported as (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, br = broad 
signal, coupling constant(s) in Hz, integration). 13C NMR spectra were recorded with 
1H-decoupling at 101 MHz using the solvent signal as reference (77.16 ppm for CDCl3). 
DEPT-135 experiments were performed to assign CH, CH2 and CH3. 
 
 
General procedure for the synthesis of the simple chiral donors 2a,21 2b and ent-2b 
 
To a dry flask were added (RS)-N-tert-butylsulfinyl amine (605 mg, 5.00 mmol) 
followed by indium powder (713 mg, 6.25 mmol), and the mixture was evacuated and 
left under Ar atmosphere. Then a solution of the corresponding cynnamaldehyde (726 
mg, 5.5 mmol) in dry THF (10 mL) was added, followed by Ti(OEt)4 (2.3 mL, 10.00 
mmol) and the reaction mixture was stirred under Ar for 1 h at 23 ºC. At this time, 3,3-
dimethylallyl bromide (873 µL, 7.5 mmol) was added and the reaction mixture was 
heated to 60 ºC for 3 h. The mixture was allowed to reach room temperature and was 
carefully added over a stirring mixture of 4:1 EtOAc/brine (50 mL). The resulted white 
suspension was filtered through a short pad of Celite, washed with EtOAc and organics 
were concentrated in vacuo. The resulted suspension was diluted in 4:1 EtOAc/Hexane 
(50 mL) and filtered again through Celite. Organics were concentrated and the residue 
(92:8 dr according 1H NMR) was purified by column chromatography (8:2 
Hexane/EtOAc). 
 
(SS,1E,3S)-N-tert-Butylsulfinyl-4,4-dimethyl-1-phenylhexa-1,5-dien-3-amine (2b) 
Compound 2b was obtained according to the general procedure as a white solid (1.218 
g, 80%, 99:1 dr according 1H NMR): mp 94.0 – 95.1 ºC. Diasteromeric excess was 
determined by HPLC of the corresponding benzamide (99:1 er by chiral HPLC on a 
Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 16.3 min, minor enantiomer tR = 21.1 min. [α]20D +163.4 (c 1.10, 
CHCl3). Rf = 0.21 (7:3 Hexane/EtOAc). IR: max/ cm-1 3289, 3057, 2958, 2924, 1637, 
1364, 1337, 1184, 1059, 996, 984, 912. 1H NMR (300 MHz, CDCl3)  7.43 – 7.27 (m, 
5H), 6.63 (d, J = 15.9 Hz, 1H), 5.96 (dd, J = 15.9, 8.8 Hz, 1H), 5.85 (dd, J = 17.4, 10.8 
Hz, 1H), 5.19 (dd, J = 10.7, 1.0 Hz, 1H), 5.13 (dd, J = 17.5, 1.1 Hz, 1H), 3.71 (d, J = 8.9 
Hz, 1H), 3.59 (br s, 1H), 1.19 (s, 9H), 1.07 (s, 3H), 1.06 (s, 3H). 13C NMR (101 MHz, 
CDCl3)  145.9 (CH), 136.8 (C), 135.3 (CH), 128.7 (CH), 127.9 (CH), 126.7 (CH), 
126.4 (CH), 114.6 (CH2), 63.3 (CH), 55.7 (C), 41.7 (C), 26.3 (CH3), 22.9 (CH3), 19.7 
(CH3). GC tR = 16.28 min. LRMS (EI) m/z (%) 249 (M+, 2), 230 (10), 180 (10), 179 
(95), 131 (14), 130 (100), 117 (13), 116 (98), 115 (41), 103 (12), 91 (12), 77 (17), 55 
(10). HRMS (EI) calcd for C18H27NOS – C4H8 249.1109, found 249.1227. 
The minor compound ((SS,1E,3R)-2b) was also isolated from the reaction described 
above as a white solid (106 mg, 7%): mp 45.1 – 46.8 ºC. [α]20D +4.0 (c 1.06, CHCl3). Rf 
= 0.34 (7:3 Hexane/EtOAc). IR max/ cm-1 3288, 3057, 2957, 2925, 1637, 1366, 1337, 
1183, 1059, 996, 985, 912. 1H NMR (400 MHz, CDCl3)  7.44 – 7.27 (m, 4H), 7.25 – 
7.16 (m, 1H), 6.62 (d, J = 15.8 Hz, 1H), 6.20 (dd, J = 15.8, 8.3 Hz, 1H), 5.86 (dd, J = 
17.4, 10.8 Hz, 1H), 5.14 (dd, J = 10.8, 1.3 Hz, 1H), 5.08 (dd, J = 17.4, 1.3 Hz, 1H), 3.61 
(t, J = 8.6 Hz, 1H), 3.30 (d, J = 9.0 Hz, 1H), 1.22 (s, 9H), 1.11 (s, 3H), 1.07 (s, 3H). 13C 
NMR (101 MHz, CDCl3)  144.4 (CH), 136.9 (C), 133.3 (CH), 128.8 (CH), 128.6 
(CH), 127.8 (CH), 126.8 (CH), 114.2 (CH2), 67.9 (CH), 56.8 (C), 41.9 (C), 24.6 (CH3), 
24.5 (CH3), 22.9 (CH3). GC tR = 16.89 min. LRMS (EI) m/z (%) 249 (M+, 2), 230 (10), 
180 (10), 179 (95), 131 (14), 130 (100), 117 (13), 116 (98), 115 (35), 103 (12), 91 (13), 
77 (17), 55(10). HRMS (EI) calcd for C18H27NOS – C4H8 249.1109, found 249.1112. 
 
(RS,1E,3R)-N-tert-Butylsulfinyl-4,4-dimethyl-1-phenylhexa-1,5-dien-3-amine (ent-
2b) 
Compound ent-2b was obtained according to the general procedure in similar yield with 
identical spectroscopic and physical data, except for [α]20D –162.6 (c 1.01, CHCl3). In 
this case (SS)-N-tert-Butylsulfinyl amine was used. 
The minor compound ((RS,1E,3S)-2b) was also isolated from the reaction described 
above as a white foam. The spectroscopic and physical data was identical to 
((SS,1E,3R)-2b), except for [α]20D –4.5 (c 0.96, CHCl3). 
 
General procedure for the synthesis of the rearranged amines 4a – 4l, 4n and 
lactam 4m 
 
To a solution of 2b [(SS,1E,3S)-2b] (92 mg, 0.3 mmol) in dry MeOH (3.7 mL) at 0 ºC 
was carefully added a solution of HCl in 1,4-dioxane (4M, 1.2 mmol, 300 µL). The 
reaction mixture was stirred for 1 h while reaching the room temperature. After removal 
of the solvent and volatiles under reduced pressure (t-BuSO2Me), the corresponding 
hydrochloride 3b was obtained as a white solid. To a solution of crude hydrochloride 3b 
in dry CH2Cl2 (2 mL) was added the corresponding aldehyde (0.36 mmol), and the 
reaction was stirred at 40 ºC for 12 h. The reaction was quenched with a solution of 
HONH2·AcOH in MeOH (0.5 M, 1.4 mL).13 The reaction mixture was diluted with 
EtOAc (5 mL) and NaOH (2 M, 5 mL), and after phase separation, the aqueous phase 
was extracted with EtOAc (3 x 5 mL). Organics were washed with NaOH (2 M, 5 mL) 
followed by brine (5 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified by column chromatography (gradient from 97:3 
CH2Cl2/MeOH to 90:10:0.05 CH2Cl2/MeOH/20% NH4OH) to provide the desired 
amines 4a – 4l and 4n. For the lactam 4m, column chromatography was carried out with 
1:3 Hexane/EtOAc. The enantiomers of some arranged products (ent-4a, ent-4m, and 
ent-4n) were prepared following the same procedure but starting from donor ent-2b.  
 
(R)-6-Methyl-1-phenyl-5-hepten-3-amine (4a) 
Following the general procedure from 3-Phenylpropanal, compound 4a was obtained as 
a yellow oil after column chromatography (48 mg, 0.234 mmol, 78%): Enantiomeric 
excess was determined by HPLC of the corresponding benzamide (88:12 er on a 
Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 30.4 min, minor enantiomer tR = 23.9 min. [α]20D -6.2 (c 0.70, CHCl3). 
Rf = 0.28 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3360, 3292, 3026, 2963, 2915, 2855, 1496, 
1453, 1376, 745, 698. 1H NMR (400 MHz, CDCl3)  7.32 – 7.27 (m, 2H), 7.23 – 7.14 
(m, 3H), 5.13 (ddd, J = 8.2, 2.7, 1.3 Hz, 1H), 2.84 (ddd, J = 12.8, 7.5, 5.3 Hz, 1H), 2.76 
(ddd, J = 13.8, 10.3, 5.8 Hz, 2H), 2.65 (ddd, J = 13.7, 10.1, 6.2 Hz, 2H), 2.19 (dt, J = 
12.3, 6.1 Hz, 1H), 2.15 – 2.05 (m, 1H), 1.85 – 1.75 (m, 1H), 1.72 (s, 3H), 1.70 – 1.65 
(m, 1H), 1.63 (s, 3H). 13C NMR (101 MHz, CDCl3)  142.2 (C), 134.7 (C), 128.5 (CH), 
128.5 (CH), 125.9 (CH), 120.7 (CH), 51.6 (CH), 38.6 (CH2), 35.9 (CH2), 32.7 (CH2), 
26.0 (CH3), 18.2 (CH3). GC tR = 12.36 min. LRMS (EI) m/z (%) 203 (M+, 0.1), 202 
(0.3), 135 (10), 134 (100), 117 (33), 91 (89), 65 (10). HRMS (EI) calcd for C14H21N 
203.1674, found 203.1726. 
 
(S)-6-Methyl-1-phenyl-5-hepten-3-amine (ent-4a) 
Following the general procedure from 3-Phenylpropanal, compound ent-4a was 
obtained with identical spectroscopic and physical data as compound 4a except for 
[α]20D +6.5 (c 0.75, CHCl3). In this case ent-2b was used as chiral donor. 
 
(R)-2-Methyl-2-tridecen-5-amine (4b) 
Following the general procedure from n-decanal, compound 4b was obtained as a 
yellow oil after column chromatography (47 mg, 0.210 mmol, 70%): Enantiomeric 
excess was determined by HPLC of the corresponding (R)−MPA derivative (89:11 er, 
see ESI). [α]20D -5.3 (c 0.95, CHCl3). Rf = 0.37 (9:1 CH2Cl2/MeOH). IR ν max/ cm-1  
3360, 3292, 2957, 2922, 2852, 1619, 1572, 815, 721 cm-1. 1H NMR (400 MHz, CDCl3) 
 5.15 (ddd, J = 8.1, 2.6, 1.3 Hz, 1H), 2.75 (br s, 1H), 2.20 – 1.87 (m, 4H), 1.73 (s, 3H), 
1.63 (s, 3H), 1.49 – 1.35 (m, 2H), 1.34 – 1.20 (m, 14H), 0.88 (t, J = 6.8 Hz, 3H). 13C 
NMR (101 MHz, CDCl3)  134.2 (C), 121.4 (CH), 51.9 (CH), 37.4 (CH2), 36.4 (CH2), 
32.1 (CH2), 29.9 (CH2), 29.8 (CH2), 29.7 (CH2), 29.5 (CH2), 26.4 (CH2), 26.1 (CH3), 
22.8 (CH2), 18.2 (CH3), 14.3 (CH3). GC tR = 12.54 min. LRMS (EI) m/z (%) 225 (M+, 
0.1), 224 (0.3), 157 (13), 156 (100), 81 (5), 69 (6), 56 (10). HRMS (EI) calcd for 
C15H31N 225.2457, found 225.2469.  
 
(S)-1-Cyclohexyl-4-methyl-3-penten-1-amine (4c) 
Following the general procedure from Cyclohexylcarbaldehyde, compound 4c was 
obtained as a yellow oil after column chromatography (35 mg, 0.195 mmol, 65%): 
Enantiomeric excess was determined by HPLC of the corresponding benzamide (82:18 
er on a Chiracel ODH column, n-Hexane/i-PrOH 95:5, 0.5 mL/min, =220 nm): major 
enantiomer tR = 20.8 min, minor enantiomer tR = 18.5 min. [α]20D -5.1 (c 0.85, CH2Cl2). 
Rf = 0.20 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3370, 3292, 2921, 2851, 1448, 1376, 890, 
817. 1H NMR (400 MHz, CDCl3)  5.15 (t, J = 7.3 Hz, 1H), 2.65 – 2.49 (m, 1H), 2.28 – 
2.10 (m, 1H), 2.10 – 1.91 (m, 2H), 1.77 (br d, J = 11.3 Hz, 3H), 1.73 (s, 3H), 1.68 (br s, 
2H), 1.63 (s, 3H), 1.38 – 0.91 (m, 7H). 13C NMR (101 MHz, CDCl3)  134.1 (C), 121.9 
(CH), 56.7 (CH), 43.1 (CH), 33.1 (CH2), 29.9 (CH2), 28.4 (CH2), 26.8 (CH2), 26.7 
(CH2), 26.5 (CH2), 26.1 (CH3), 18.2 (CH3). GC tR = 10.73 min.  LRMS (EI) m/z (%) 
181 (M+, 0.1), 180 (0.3), 113 (8), 112 (100), 98 (9), 95 (37), 81 (12), 67 (6), 55 (6). 
HRMS (EI) calcd for C12H23N 181.1830, found 181.1841.  
 
(5R,7S)-2,7,11-Trimethyldodeca-2,10-dien-5-amine (4d) 
Following the general procedure from (S)-Citronellal, compound 4d was obtained as a 
yellow oil after column chromatography (42 mg, 0.189 mmol, 63%): Diastereomeric 
excess was determined by comparing the 13C NMR spectra of both diasteroisomers 4d 
and 4e (82:18 dr, see ESI). [α]20D +5.0 (c 1.07, CHCl3). Rf = 0.29 (9:1 CH2Cl2/MeOH). 
IR max/ cm-1 3350, 2963, 2913, 2859, 1727, 1668, 1450, 1376, 828, 750. 1H NMR (300 
MHz, CDCl3)  5.19 – 5.06 (m, 2H), 2.87 (tt, J = 9.6, 5.0 Hz, 1H), 2.35 – 1.90 (m, 6H), 
1.73 (d, J = 0.6 Hz, 3H), 1.68 (d, J = 1.0 Hz, 3H), 1.64 (s, 3H), 1.60 (s, 3H), 1.43 – 1.09 
(m, 5H), 0.89 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3)  134.4 (C), 131.3 (C), 
124.9 (CH), 121.2 (CH), 49.4 (CH), 44.7 (CH2), 37.9 (CH2), 36.9 (CH2), 29.4 (CH), 
26.1 (CH3), 25.9 (CH3), 25.6 (CH2), 19.3 (CH3), 18.2 (CH3), 17.8 (CH3). GC tR = 12.04 
min. LRMS (EI) m/z (%) 203 (M+, 0.1), 155 (12), 154 (100), 137 (19), 112 (6), 98 (7), 
96 (5), 95 (38), 82 (89), 70 (13), 69 (39), 67 (10). HRMS (EI) calcd for C15H29N 
223.2300, found 223.2279.  
 
(5S,7S)-2,7,11-Trimethyldodeca-2,10-dien-5-amine (4e) 
Following the general procedure from (S)-Citronellal, but using ent-2b as chiral donor, 
compound 4e was obtained as a yellow oil after column chromatography (50 mg, 0.224 
mmol, 75%): Diastereomeric excess was determined by comparing the 13C NMR 
spectra of both diasteroisomers 4d and 4e (93:7 dr, see ESI) [α]20D +10.6 (c 0.80, 
CH2Cl2). Rf  = 0.27 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3351, 2963, 2913, 2848, 1727, 
1668, 1450, 1376, 829, 754. 1H NMR (300 MHz, CDCl3)  5.19 – 5.06 (m, 2H), 2.88 
(dt, J = 12.0, 7.4 Hz, 1H), 2.26 (br s, 2H), 2.19 – 2.09 (m, 1H), 2.06 –1.90 (m, 3H), 1.73 
(d, J = 0.6 Hz, 3H), 1.68 (d, J = 1.0 Hz, 3H), 1.64 (s, 3H), 1.60 (s, 3H), 1.58 – 1.51 (m, 
1H), 1.44 – 1.30 (m, 2H), 1.27 – 1.07 (m, 2H), 0.91 (d, J = 6.6 Hz, 3H). 13C NMR (101 
MHz, CDCl3)  134.5 (C), 131.4 (C), 124.9 (CH), 121.1 (CH), 49.6 (CH), 44.9 (CH2), 
36.9 (CH2), 36.0 (CH2), 29.5 (CH), 26.1 (CH3), 25.9 (CH3), 25.4 (CH2), 20.3 (CH3), 
18.2 (CH3), 17.8 (CH3). GC tR = 12.16 min. LRMS (EI) m/z (%) 223 (M+, 0.1), 155 
(12), 154 (100), 137 (19), 112 (6), 98 (7), 95 (38), 82 (9), 81 (89), 70 (13), 69 (39), 67 
(10). HRMS (EI) calcd for C15H29N 223.2300, found 223.2283.  
 
(E,S)-6-Methyl-1-phenylhepta-1,5-dien-3-amine (4f) 
Following the general procedure from Cinnamaldehyde, compound 4f was obtained as a 
yellow oil after column chromatography (48 mg, 0.240 mmol, 80%): Enantiomeric 
excess was determined by HPLC of the corresponding benzamide (89:11 er on a 
Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 37.7 min, minor enantiomer tR = 42.0 min. [α]20D -8.5 (c 0.92, CH2Cl2). 
Rf = 0.15 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3370, 3301, 2917, 2859, 1448, 1376, 812. 
1H NMR (400 MHz, CDCl3)  7.42 – 7.29 (m, 4H), 7.24 – 7.17 (m, 1H), 6.51 (d, J = 
15.9 Hz, 1H), 6.21 (dd, J = 15.9, 6.8 Hz, 1H), 5.30 – 5.05 (m, 1H), 3.53 (q, J = 6.7 Hz, 
1H), 2.24 (t, J = 7.0 Hz, 2H), 1.92 (br s, 2H), 1.73 (s, 3H), 1.65 (s, 3H). 13C NMR (101 
MHz, CDCl3)  137.3 (C), 134.8 (CH), 134.3 (C), 129.1 (CH), 128.7 (CH), 127.4 (CH), 
126.4 (CH), 120.5 (CH), 54.3 (CH), 36.6 (CH2), 26.1 (CH3), 18.2 (CH3). GC tR = 13.09 
min. LRMS (EI) m/z (%) 201 (M+, 0.1), 133 (11), 132 (100), 130 (9), 117 (8), 115 (31). 
HRMS (EI) calcd for C14H19N 201.1517, found 201.1538.  
 
(S)-1-(2-Chlorophenyl)-4-methyl-3-penten-1-amine (4g) 
Following the general procedure from 2-Chlorobenzaldehyde, compound 4g was 
obtained as a yellow oil after column chromatography (32 mg, 0.156 mmol, 52%): 
Enantiomeric excess was determined by HPLC of the corresponding benzamide (92:8 er 
on a Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 18.4 min, minor enantiomer tR = 14.9 min. [α]20D –69.8 (c 1.50, CHCl3). 
Rf = 0.50 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3370, 3282, 3060, 2967, 2913, 2853, 1668, 
1439, 1035, 854, 694. 1H NMR (300 MHz, CDCl3)  7.53 (dd, J = 7.7, 1.6 Hz, 1H), 
7.33 (dd, J = 7.8, 1.4 Hz, 1H), 7.29 – 7.24 (m, 1H), 7.19 – 7.13 (m, 1H), 5.17 (tdd, J = 
6.7, 2.8, 1.4 Hz, 1H), 4.42 (dd, J = 8.3, 4.8 Hz, 1H), 2.44 (dt, J = 11.6, 5.7 Hz, 1H), 2.36 
– 2.19 (m, 1H), 1.72 (d, J = 0.7 Hz, 3H), 1.62 (br s, 2H), 1.61 (s, 3H). 13C NMR (101 
MHz, CDCl3)  143.4 (C), 135.0 (C), 133.0 (C), 129.6 (CH), 127.9 (CH), 127.4 (CH), 
127.1 (CH), 120.8 (CH), 52.4 (CH), 36.4 (CH2), 26.0 (CH3), 18.1 (CH3). GC tR = 11.89 
min. LRMS (EI) m/z (%) 209 (0.1, M+), 142 (34), 141 (9), 140 (100), 115 (8), 113 (5, 
78 (3, 77 (13). Anal. Calc’d for C12H16ClN: C 68.73, H 7.69, N 6.68. Found: C 68.99, H 
7.52, N 6.58. 
 
(S)-1-(3-Chlorophenyl)-4-methyl-3-penten-1-amine (4h) 
Following the general procedure from 3-Chlorobenzaldehyde, compound 4h was 
obtained as a yellow oil after column chromatography (27 mg, 0.129 mmol, 45%): 
Enantiomeric excess was determined by HPLC of the corresponding benzamide (89:11 
er on a Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 29.5 min, minor enantiomer tR = 18.9 min. [α]20D –30.2 (c 0.87, CHCl3). 
Rf = 0.34 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3370, 3281, 2968, 2913, 1596, 1573, 1432, 
784, 697. 1H NMR (300 MHz, CDCl3)  7.36 (t, J = 1.7 Hz, 1H), 7.26 – 7.16 (m, 3H), 
5.19 – 4.97 (m, 1H), 3.92 (t, J = 6.7 Hz, 1H), 2.32 (t, J = 7.0 Hz, 2H), 1.88 (d, J = 3.6 
Hz, 1H), 1.71 (d, J = 1.0 Hz, 3H), 1.64 (br s, 1H), 1.59 (s, 3H). 13C NMR (101 MHz, 
CDCl3)  148.5 (C), 135.1 (C), 134.3 (C), 129.7 (CH), 127.1 (CH), 126.8 (CH), 124.8 
(CH), 120.6 (CH), 56.0 (CH), 38.5 (CH2), 26.0 (CH3), 18.1 (CH3). GC tR = 12.24 min. 
LRMS (EI) m/z (%) 206 (1), 142 (32), 141 (9), 140 (100), 138 (3), 77 (13). HRMS 
(ES+) calcd for C12H17ClN 210.1050, found 210.1044. 
 
(S)-1-(4-Chlorophenyl)-4-methyl-3-penten-1-amine (4i) 
Following the general procedure from 4-Chlorobenzaldehyde, compound 4i was 
obtained as a yellow oil after column chromatography (18 mg, 0.09 mmol, 30%): 
Enantiomeric excess was determined by HPLC of the corresponding benzamide (89:11 
er on a Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 32.8 min, minor enantiomer tR = 21.4 min. [α]20D –25.5 (c 1.50, CHCl3). 
Rf = 0.33 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3375, 3286, 2968, 2912, 1859, 1668, 1489, 
1089, 1013, 822. 1H NMR (300 MHz, CDCl3)  7.30 (s, 4H), 5.10 (tt, J = 7.3, 1.4 Hz, 
1H), 3.95 (t, J = 7.0 Hz, 1H), 2.32 (t, J = 7.1 Hz, 2H), 1.72 (d, J = 0.9 Hz, 3H), 1.62 (br 
s, 2H), 1.60 (s, 3H). 13C NMR (101 MHz, CDCl3)  144.7 (C), 135.0 (C), 132.5 (C), 
128.5 (CH), 127.9 (CH), 120.7 (CH), 55.8 (CH), 38.5 (CH2), 26.0 (CH3), 18.1 (CH3). 
GC tR = 12.18 min. LRMS (EI) m/z (%) 143 (9), 142 (34), 141 (28), 140 (100), 138 (8), 
115 (8), 113 (21), 78 (6), 77 (36). HRMS (EI) calcd for C12H16ClN 209.0971, found 
209.1251. 
 
(S)-1-(3-Bromophenyl)-4-methyl-3-penten-1-amine (4j) 
Following the general procedure from 3-Bromobenzaldehyde, compound 4j was 
obtained as a yellow oil after column chromatography (37 mg, 0.146 mmol, 50%): 
Enantiomeric excess was determined by HPLC of the corresponding benzamide (89:11 
er on a Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 31.8 min, minor enantiomer tR = 20.8 min. [α]20D –22.6 (c 1.20, CHCl3). 
Rf = 0.33 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3370, 3301, 2966, 2912, 1593, 1567, 1427, 
1068, 782. 1H NMR (300 MHz, CDCl3)  7.51 (t, J = 1.7 Hz, 1H), 7.39 – 7.33 (m, 1H), 
7.29 – 7.23 (m, 1H), 7.18 (t, J = 7.7 Hz, 1H), 5.09 (tdd, J = 6.0, 2.8, 1.4 Hz, 1H), 3.91 
(t, J = 6.7 Hz, 1H), 2.32 (t, J = 7.0 Hz, 2H), 1.72 (br s, 2H), 1.70 (d, J = 0.9 Hz, 3H), 
1.58 (s, 3H). 13C NMR (101 MHz, CDCl3)  148.7 (C), 135.1 (C), 130.1 (C), 130.0 
(CH), 129.7 (CH), 125.2 (CH), 122.6 (CH), 120.6 (CH), 55.9 (CH), 38.4 (CH2), 26.0 
(CH3), 18.1 (CH3). GC tR = 12.87 min. LRMS (EI) m/z (%) 254 (0.1), 187 (12), 186 
(98), 185 (13), 184 (100), 182 (2), 157 (7), 104 (9), 77 (13). HRMS (ES+) calcd for 
C12H17BrN 254.0544, found 254.0548.  
 (S)-1-(4-Nitrophenyl)-4-methyl-3-penten-1-amine (4k) 
Following the general procedure from 4-Nitrobenzaldehyde, compound 4k was obtained 
as a yellow oil after column chromatography (55 mg, 0.250 mmol, 83%): Enantiomeric 
excess was determined by HPLC of the corresponding benzamide (90:10 er on a 
Chiracel ODH column, n-Hexane/i-PrOH 90:10, 1 mL/min, =220 nm): major 
enantiomer tR = 36.5 min, minor enantiomer tR = 30.1 min.  [α]20D –21.7 (c 1.10, 
CHCl3). Rf = 0.36 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3376, 2971, 2911, 2848, 1597, 
1507, 1342, 856, 751, 701. 1H NMR (300 MHz, CDCl3)  8.19 (dd, J = 8.8, 2.1 Hz, 
2H), 7.54 (dd, J = 8.6, 2.1 Hz, 2H), 5.08 (tt, J = 7.4, 1.4 Hz, 1H), 4.08 (t, J = 6.7 Hz, 
1H), 2.34 (t, J = 7.1 Hz, 2H), 1.71 (d, J = 0.7 Hz, 3H), 1.64 (br s, 2H), 1.57 (s, 3H). 13C 
NMR (101 MHz, CDCl3)  153.8 (C), 147.0 (C), 135.8 (C), 127.4 (CH), 127.4 (CH), 
123.7 (CH), 123.7 (CH), 119.9 (CH), 55.9 (CH), 38.5 (CH2), 26.0 (CH3), 18.1 (CH3). 
GC tR = 14.37 min. LRMS (EI) m/z (%) 152 (9), 151 (100), 121 (4), 105 (31), 104 (13), 
93 (5), 78 (5), 77 (6). HRMS (EI) calcd for C12H16N2O2 220.1212, found 220.1202.   
 
(S)-1-(5-Fluoro-2-nitrophenyl)-4-methyl-3-penten-1-amine (4l) 
Following the general procedure from 5-Fluoro-2-nitrobenzaldehyde, compound 4l was 
obtained as a yellow oil after column chromatography (42 mg, 0.176 mmol, 60%): 
Enantiomeric excess was determined by HPLC of the corresponding benzamide (94:6 er 
on a Chiracel ODH column, n-Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major 
enantiomer tR = 37.8 min, minor enantiomer tR = 28.0 min. [α]20D –89.8 (c 0.75, CHCl3). 
Rf = 0.53 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3390, 3302, 2970, 2916, 2849, 1584, 1512, 
1352, 851, 757, 704. 1H NMR (400 MHz, CDCl3)  7.88 (dd, J = 9.0, 5.1 Hz, 1H), 7.59 
(dd, J = 9.9, 2.8 Hz, 1H), 7.03 (ddd, J = 9.0, 7.1, 2.8 Hz, 1H), 5.13 (ttd, J = 6.6, 2.7, 1.3 
Hz, 1H), 4.59 (ddd, J = 8.2, 4.8, 1.6 Hz, 1H), 2.47 – 2.36 (m, 1H), 2.34 – 2.23 (m, 1H), 
1.72 (s, 3H), 1.60 (br s, 5H). 13C NMR (101 MHz, CDCl3)  165.1 (d, J = 255.3 Hz, C), 
145.3 (d, J = 8.0 Hz, C), 145.2 (C), 136.1 (C), 127.1 (d, J = 9.5 Hz, CH), 120.0 (CH), 
115.5 (d, J = 24.4 Hz, CH), 114.7 (d, J = 24.4 Hz, CH), 50.7 (CH), 37.5 (CH2), 26.0 
(CH3), 18.1 (CH3). GC tR = 13.04 min. LRMS (EI) m/z (%) 170 (9), 169 (100), 152 (3), 
123 (17), 122 (17), 122 (23), 69 (4). HRMS (EI) calcd for C12H16N2O2F 239.1196, 
found 239.1197. 
 
(R)-5-Prenyl-2-pyrrolidinone (4m) 
Following the general procedure from Methyl 4-oxobutanoate,22 compound 4m was 
obtained as a yellow oil after column chromatography (35 mg, 0.225 mmol, 75%): 
Enantiomeric excess was directly determined by HPLC of the lactam (88:12 er on a 
Chiracel ODH column, n-Hexane/i-PrOH 90:10, 1 mL/min, =220 nm): major 
enantiomer tR = 8.1 min, minor enantiomer tR = 9.5 min. [α]20D –14.5 (c 0.90, CHCl3). 
Rf = 0.20 (1:3 Hexane:EtOAc). IR max/ cm-1 3210, 3100, 2969, 2915, 1689, 1440, 
1424, 1343, 856. 1H NMR (300 MHz, CDCl3)  6.05 (br s, 1H), 5.09 (tdd, J = 6.9, 2.8, 
1.4 Hz, 1H), 3.65 (p, J = 6.6 Hz, 1H), 2.38 – 2.29 (m, 2H), 2.28 – 2.14 (m, 3H), 1.82 – 
1.74 (m, 1H), 1.72 (s, 3H), 1.63 (s, 3H). 13C NMR (101 MHz, CDCl3)  178.1 (C), 
135.5 (C), 119.3 (CH), 54.7 (CH), 35.3 (CH2), 30.3 (CH2), 26.9 (CH2), 26.0 (CH3), 18.1 
(CH3). GC tR = 11.30 min. LRMS (EI) m/z (%) 153 (M+, 2), 85 (5), 84 (100), 69 (2), 56 
(6), 55 (3). HRMS (ES+) calcd for C9H16NO 154.1232, found 154.1231. 
 
(S)-5-Prenyl-2-pyrrolidinone (ent-4m) 
Following the general procedure from Methyl 4-oxobutanoate, compound ent-4m was 
obtained with identical spectroscopic and physical data as compound 4m except for 
[α]20D +14.1 (c 0.95, CHCl3). In this case ent-2b was used as chiral donor. 
 
(R)-Ethyl 6-amino-9-methyl-8-decenoate (4n) 
Following the general procedure from Ethyl 6-oxohexanoate,23 but in a larger scale 
(1.45 mmol of donor 2b), compound 4n was obtained as a yellow oil after column 
chromatography (286 mg, 1.261 mmol, 87%): Enantiomeric excess was determined by 
HPLC of the corresponding benzamide (85:15 er on a Chiracel ODH column, n-
Hexane/i-PrOH 95:5, 1 mL/min, =220 nm): major enantiomer tR = 20.5 min, minor 
enantiomer tR = 30.1 min. [α]20D –5.3 (c 1.20, CHCl3). Rf = 0.30 (1:3 Hexane:EtOAc). 
IR max/ cm-1 3439, 3370, 2972, 2928, 2860, 1733, 1248, 1179, 851, 722. 1H NMR (300 
MHz, CDCl3)  5.13 (dd, J = 7.9, 6.9 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 2.77 (br s, 1H), 
2.31 (t, J = 7.4 Hz, 2H), 2.23 (br s, 2H), 2.18 – 1.94 (m, 2H), 1.73 (s, 3H), 1.70 – 1.65 
(m, 1H), 1.63 (s, 3H), 1.62 – 1.54 (m, J = 13.0 Hz, 1H), 1.55 – 1.40 (m, 2H), 1.40 – 
1.30 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3)  173.8 (C), 134.5 
(C), 121.1 (CH), 60.3 (CH2), 51.7 (CH), 36.8 (CH2), 36.3 (CH2), 34.4 (CH2), 26.03 
(CH3), 25.9 (CH2), 25.1 (CH2), 18.2 (CH3), 14.4 (CH3). GC tR = 12.46 min. LRMS (EI) 
m/z (%) 227 (M+, 0.1), 182 (9), 159 (9), 158 (100), 140 (13), 113 (8), 112 (72), 84 (17), 
81 (12), 69 (27), 67 (17), 56 (23). Anal. Calc’d for C13H25NO2: C 68.68, H 11.08, N 
6.16. Found: C 68.30, H 10.71, N 5.79. 
 
(S)-Ethyl 6-amino-9-methyl-8-decenoate (ent-4n) 
Following the general procedure from Ethyl 6-oxohexanoate, compound ent-4n was 
obtained with identical spectroscopic and physical data as compound 4n except for 
[α]20D +5.5 (c 0.95, CHCl3). In this case ent-2b was used as chiral donor. 
 
(2R,7R)-2-Methyl-7-prenylazepane (4o) 
Following the general procedure from 6-Oxoheptanal.24 However, instead of adding 
HONH2·AcOH to the arranged mixture, NaBH3CN (1.8 mmol, 114 mg) was added and 
the reaction was stirred for 12 h at room temperature. Then, the reaction mixture was 
diluted with EtOAc (5mL) and NaOH (2 M, 5 mL), and extracted with EtOAc (3 x 
5mL), washed with NaOH (2 M, 5 mL) and brine (5 mL). Organics were dried over 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
column chromatography (gradient from 97:3 CH2Cl2/MeOH to 90:10:0.05 
CH2Cl2/MeOH/20% NH4OH) to provide the desired free amine 4o as a yellow oil (20 
mg, 0.110 mmol, 37%): Enantiomeric excess was determined by HPLC of the 
corresponding benzamide (86:14 er on a Chiracel ODH column, n-Hexane/i-PrOH 98:2, 
1 mL/min, =220 nm): major enantiomer tR = 17.0 min, minor enantiomer tR = 20.8 
min. [α]20D –1.5 (c 1.10, CHCl3). Rf = 0.37 (9:1 CH2Cl2/MeOH). IR max/ cm-1 3311, 
2962, 2924, 2855, 1678, 1450, 1375, 751. 1H NMR (300 MHz, CDCl3)  5.15 – 5.04 
(m, 1H), 2.82 (dqd, J = 9.6, 6.4, 3.3 Hz, 1H), 2.67 (ddd, J = 10.0, 7.2, 3.2 Hz, 1H), 2.24 
– 2.02 (m, 2H), 1.78 – 1.73 (m, 2H), 1.72 (d, J = 0.9 Hz, 3H), 1.71 – 1.64 (m, 3H), 1.62 
(s, 3H), 1.61 – 1.50 (m, 2H), 1.49 – 1.36 (m, 2H), 1.14 (d, J = 6.4 Hz, 3H). 13C NMR 
(101 MHz, CDCl3)  134.4 (C), 121.5 (CH), 59.7 (CH), 55.2 (CH), 38.0 (CH2), 35.9 
(CH2), 35.7 (CH2), 25.8 (CH3), 25.3 (CH2), 25.0 (CH2), 23.6 (CH3), 18.0 (CH3). GC tR = 
9.19 min. LRMS (EI) m/z (%) 181 (M+, 1), 113 (8), 112 (100), 95 (10), 82 (5), 69 (7), 
56 (6). HRMS (ES+) calcd for C12H24N 182.1909, found 182.1906.  
 
(2S,7S)-2-Methyl-7-prenylazepane (ent-4o) 
Following the general procedure from 6-Oxoheptanal, compound ent-4o was obtained 
with identical spectroscopic and physical data as compound 4o except for [α]20D +1.8 (c 
0.95, CHCl3). In this case ent-2b was used as chiral donor. 
 
General procedure for the synthesis of pyrrolidines 5a and 5n. 
To a solution of free amine 4a or 4n (1.17 mmol) in CH2Cl2 (11 mL) at 0 ºC, were 
added Et3N (248 µL, 1.75 mmol) and p-nitrobenzenesulfonyl chloride (310 mg, 1.40 
mmol). The solution was allowed to warm to 25 ºC and stirred over 12 h. The reaction 
was quenched with HCl (1M), and after phase separation, the organic layer was washed 
with NaOH (1M), followed by water and brine. Evaporation of the solvent under 
vacuum gave crude 4a-Ns or 4n-Ns, which were purified by column chromatography 
(9:1 Hexane/EtOAc) and totally characterized (see physical and spectroscopical data of 
the p-nosylate derivatives below). At this point, trifluoromethanesulfonic acid (19 µL, 
0.2 mmol) was added to a solution of 4a-Ns or 4n-Ns in dry toluene (70 mL) and the 
reaction mixture was stirred at 0 ºC for 1 h. After concentration under reduced pressure, 
the residue was purified by column chromatography (9:1 Hexane/EtOAc) to provide the 
desired pyrrolidines 5a or 5n. 
 
(R)-p-Nosylate of 4a (4a-Ns) 
Compound 4a-Ns was obtained according to the general procedure as a white solid (392 
mg, 1.01 mmol, 86%): mp 72.8 – 75.2 ºC. [α]20D –8.6 (c 0.95, CHCl3). Rf = 0.15 (9:1 
Hexane/EtOAc). IR max/ cm-1 3289, 3027, 2926, 2859, 1605, 1528, 1347, 1308, 1161, 
1092, 852, 735. 1H NMR (300 MHz, CDCl3)  8.31 (d, J = 9.0 Hz, 2H), 7.98 (d, J = 8.9 
Hz, 2H), 7.29 – 7.27 (m, 1H), 7.25 – 7.23 (m, 1H), 7.23 – 7.16 (m, 1H), 7.09 – 7.05 (m, 
2H), 4.84 (ddd, J = 7.5, 4.4, 1.3 Hz, 1H), 4.56 (br s, 1H), 3.41 – 3.26 (m, 1H), 2.67 – 
2.50 (m, 2H), 2.18 (dt, J = 13.6, 6.7 Hz, 1H), 2.13 – 2.05 (m, 1H), 1.88 – 1.78 (m, 1H), 
1.73 (ddt, J = 14.0, 9.3, 7.0 Hz, 1H), 1.61 (d, J = 0.6 Hz, 3H), 1.51 (s, 3H). 13C NMR 
(101 MHz, CDCl3)  150.0 (C), 147.0 (C), 141.0 (C), 136.5 (C), 128.7 (CH), 128.4 
(CH), 128.4 (CH), 126.3 (CH), 124.4 (CH), 118.2 (CH), 54.4 (CH), 36.6 (CH2), 33.4 
(CH2), 31.9 (CH2), 26.1 (CH3), 18.1 (CH3). GC tR = 24.32 min. LRMS (EI) m/z (%) 320 
(4), 319 (22), 289 (4), 156 (10), 132 (5), 122 (5), 118 (10), 117 (100), 92 (12), 91 (93), 
77 (4), 65 (5). HRMS (ES+) calcd for C20H25N2O4S 389.1535, found 389.1539. 
 
(R)-p-Nosylate of 4n (4n-Ns) 
Compound 4n-Ns was obtained according to the general procedure as a yellow wax 
(420 mg, 1.02 mmol, 88%): [α]20D +6.0 (c 0.95, CHCl3). Rf = 0.28 (8:2 Hexane/EtOAc). 
IR max/ cm-1 3280, 2931, 2863, 1730, 1529, 1348, 1307, 1160, 1091, 853, 735. 1H 
NMR (300 MHz, CDCl3)  8.35 (d, J = 9.0 Hz, 2H), 8.04 (d, J = 9.0 Hz, 2H), 4.83 (ddd, 
J = 7.5, 6.1, 1.4 Hz, 1H), 4.54 (d, J = 8.4 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.38 – 3.23 
(m, 1H), 2.22 (t, J = 7.4 Hz, 2H), 2.18 – 1.94 (m, 2H), 1.60 (s, 3H), 1.55 (d, J = 7.5 Hz, 
2H), 1.50 (s,3H), 1.49 – 1.28 (m, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.22 – 1.13 (m, 1H). 13C 
NMR (101 MHz, CDCl3)  173.6 (C), 150.1 (C), 147.3 (C), 136.2 (C), 128.4 (CH), 
124.4 (CH), 118.4 (CH), 60.5 (CH2), 54.8 (CH), 34.8 (CH2), 34.1 (CH2), 33.6 (CH2), 
26.0 (CH3), 25.2 (CH2), 24.7 (CH2), 18.1 (CH3), 14.4 (CH3). GC tR = 25.88 min. LRMS 
(EI) m/z (%) 344 (6), 343 (36), 313 (8), 299 (9), 298 (16), 297 (100), 281 (9), 269 (11), 
207 (24), 186 (6), 157 (5), 156 (17), 122 (13), 95 (28), 69 (71). HRMS (ES+) calcd for 
C19H29N2O6S 413.1746, found 413.1732. 
 
(R)-2,2-dimethyl-5-phenethyl-1-(p-nosyl)pyrrolidine (5a) 
Compound 5a was obtained according to the general procedure as a white solid (361 
mg, 0.93 mmol, 93%): mp 86.8 – 89.5 ºC. [α]20D –59.4 (c 0.95, CHCl3). Rf = 0.30 (9:1 
Hexane/EtOAc). IR max/ cm-1 2959, 29223, 2859, 1525, 1455, 1342, 1151, 855, 738. 
1H NMR (300 MHz, CDCl3)  8.20 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.8 Hz, 2H), 7.36 – 
7.30 (m, 2H), 7.30 – 7.26 (m, 0.7H), 7.26 – 7.23 (m, 0.3H), 7.21 – 7.14 (m, 2H), 3.68 – 
3.57 (m, 1H), 2.72 (ddd, J = 13.4, 8.5, 4.6 Hz, 1H), 2.50 (dt, J = 13.9, 8.4 Hz, 1H), 2.33 
– 2.22 (m, 1H), 2.07 – 1.93 (m, 1H), 1.85 – 1.69 (m, 4H), 1.60 (s, 3H), 1.31 (s, 3H). 13C 
NMR (101 MHz, CDCl3)  149.6 (C), 147.6 (C), 141.0 (C), 128.8 (CH), 128.7 (CH), 
128.7 (CH), 126.3 (CH), 124.1 (CH), 67.1 (C), 61.4 (CH), 40.6 (CH2), 36.6 (CH2), 32.9 
(CH2), 31.5 (CH3), 27.1 (CH2), 26.6 (CH3). GC tR = 24.01 min. LRMS (EI) m/z (%) 373 
(5), 15 (100), 253 (5), 156 (5), 122 (12), 117 (6), 105 (5), 98 (14), 97 (8), 96 (6), 91 
(25), 83 (6), 82 (17), 81 (82), 65 (4). HRMS (ES+) calcd for C20H25N2O4S 389.1535, 
found 389.1538. 
 
(R)-Ethyl 5-(5,5-dimethyl-1-(p-nosyl)pyrrolidin-2-yl)pentanoate (5n) 
Compound 5n was obtained according to the general procedure as a yellow oil (380 mg, 
0.92 mmol, 93%): [α]20D –29.3 (c 0.95, CHCl3). Rf = 0.40 (8:2 Hexane/EtOAc). IR max/ 
cm-1 3110, 2970, 2939, 2869, 1731, 1528, 1462, 1347, 1305, 1152, 1092, 854, 736. 1H 
NMR (300 MHz, CDCl3)  8.33 (d, J = 9.0 Hz, 2H), 8.05 (d, J = 9.1 Hz, 2H), 4.13 (q, J 
= 7.1 Hz, 2H), 3.80 (ddd, J = 9.4, 6.6, 2.9 Hz, 1H), 2.29 (t, J = 7.4 Hz, 2H), 2.07 – 1.59 
(m, 7H), 1.58 (s, 3H), 1.57 – 1.42 (m, 2H), 1.36 – 1.32 (m, 1H), 1.31 (s, 3H), 1.26 (t, J = 
7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3)  173.6 (C), 149.7 (C), 148.7 (C), 128.5 
(CH), 124.2 (CH), 66.7 (C), 62.9 (CH), 60.4 (CH2), 40.7 (CH2), 35.4 (CH2), 34.2 (CH2), 
31.3 (CH3), 27.3 (CH2), 27.0 (CH3), 26.2 (CH2), 24.8 (CH2), 14.4 (CH3). GC tR = 26.48 
min. LRMS (EI) m/z (%) 367 (10), 285 (5), 284 (15), 283 (100), 253 (3), 226 (33), 97 
(5), 82 (9), 81 (42). HRMS (ES+) calcd for C19H29N2O6S 413.1746, found 413.1740. 
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